Filing Flows › Viridian Therapeutics (VRDN) › Q1 2026
Viridian Therapeutics (VRDN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Viridian Therapeutics (VRDN) reported revenue of $141K for the first quarter 2026 (Q1 2026), +96% from a year earlier and +7% from the quarter before.
Viridian Therapeutics, Q1 2026: revenue $141K (+96% year over year), net loss $105M, operating cash flow −$120M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $141K | +7% | +96% |
| Operating profit | −$116M | — | — |
| Net earnings | −$105M | — | — |
| Operating cash flow | −$120M | — | — |
What changed
Revenue was $141K in Q1 2026, up 96% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $116.2M, an operating margin of -82389.4%. Total costs grew 24% against revenue growth of 96%. The fastest-growing cost line was SG&A (+126%). The quarter ended with a net loss of $104.9M, narrower than the previous quarter's $120.4M loss.
Operating cash flow was −$119.7M. Non-cash charges added back $121K of depreciation and amortization and $13.4M of share-based compensation. Working capital and other items used $28.3M. Capital expenditures of $23K exceeded it, leaving free cash flow of −$119.7M.
Questions
What was Viridian Therapeutics' revenue in the first quarter 2026?
Viridian Therapeutics (VRDN) reported revenue of $141K for the first quarter 2026 (Q1 2026), +96% from a year earlier and +7% from the quarter before.